Aprogen pharmaceuticals,Inc. (003060.KS)
KRW 704.0
(-4.22%)
KRW 704.0
(-4.22%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 87.36 Billion | 65.19 Billion | 56.48 Billion | 53.31 Billion | 50.9 Billion | 45.39 Billion |
| Cost of Revenue | 99.4 Billion | 37.9 Billion | 31.03 Billion | 30.11 Billion | 30.34 Billion | 26.61 Billion |
| Gross Profit | -12.04 Billion | 27.28 Billion | 25.44 Billion | 23.2 Billion | 20.55 Billion | 18.78 Billion |
| Operating Expenses | 58.64 Billion | 32.99 Billion | 29.24 Billion | 24.17 Billion | 22.48 Billion | 19.6 Billion |
| Selling, General and Administrative Expenses | 43.64 Billion | 17.83 Billion | 14.43 Billion | 11.25 Billion | 10.83 Billion | 9.06 Billion |
| Research and Development Expenses | 14.99 Billion | 2.18 Billion | 1.73 Billion | 697.7 Million | 336.12 Million | 191.62 Million |
| Other Expenses | - | 12.97 Billion | 13.07 Billion | 12.22 Billion | 11.32 Billion | 98.11 Million |
| Cost and Expenses | 158.05 Billion | 70.9 Billion | 60.28 Billion | 54.29 Billion | 52.83 Billion | 46.22 Billion |
| Operating Income | -69.95 Billion | 12.8 Billion | 10.48 Billion | 13.95 Billion | -1.93 Billion | -825.58 Million |
| Interest Expense | 3.66 Billion | 274.4 Million | 31.13 Million | 49.05 Million | 3.32 Billion | 7.4 Billion |
| Income Tax Expense | 1.94 Billion | 1.26 Billion | 679.69 Million | -2.27 Billion | 409.25 Million | 263 Million |
| Earnings before Tax | -113.38 Billion | 6.84 Billion | 9.83 Billion | 16.64 Billion | -3.05 Billion | -952.4 Million |
| Net Income | -118.26 Billion | 5.58 Billion | 8.1 Billion | 18.91 Billion | -3.46 Billion | -1.21 Billion |
| Earnings Per Share Basic | -1421.09 | 104.07 | 55.98 | 130.70 | -18.73 | -8.03 |
| Earnings Per Share Diluted | -1421.09 | 104.07 | 151.99 | 447.15 | -18.73 | -8.03 |
| Weighted Average Shares Outstanding | 83.22 Million | 53.65 Million | 144.73 Million | 144.73 Million | 185.08 Million | 151.31 Million |
| Weighted Average Shares Outstanding (Diluted) | 83.22 Million | 53.65 Million | 53.31 Million | 42.3 Million | 185.08 Million | 151.31 Million |
| Gross Margin | -0.14 | 0.42 | 0.45 | 0.44 | 0.40 | 0.41 |
| EBIT Margin | -0.56 | 0.23 | 0.22 | 0.30 | -0.05 | 0.23 |
| Profit Margin | -1.35 | 0.09 | 0.14 | 0.35 | -0.07 | -0.03 |
| EBITDA | -49.29 Billion | 16 Billion | 11.38 Billion | 16.91 Billion | -2.8 Billion | 7.91 Billion |
| Earnings Before Tax Margin | -0.80 | 0.20 | 0.19 | 0.26 | -0.04 | -0.02 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 15.19 Billion | 15.6 Billion | 87.36 Billion | 22.7 Billion | 20.13 Billion | 27.07 Billion |
| Cost of Revenue | 15.02 Billion | 14.69 Billion | 99.4 Billion | 27.24 Billion | 23.28 Billion | 27.52 Billion |
| Gross Profit | 169.58 Million | 907.62 Million | -12.04 Billion | -4.53 Billion | -3.15 Billion | -449.7 Million |
| Operating Expenses | 11.48 Billion | 12.89 Billion | 58.64 Billion | 36.18 Billion | -11.2 Billion | -12.4 Billion |
| Selling, General and Administrative Expenses | 5.42 Billion | 7.74 Billion | - | 30.08 Billion | 11.2 Billion | 12.4 Billion |
| Research and Development Expenses | 6.06 Billion | 5.15 Billion | - | 6.09 Billion | 3.6 Billion | 15.8 Billion |
| Other Expenses | -12.36 Billion | 536.84 Million | 225.53 Million | -4.98 Billion | -22.41 Billion | -24.81 Billion |
| Cost and Expenses | 26.5 Billion | 27.59 Billion | 158.05 Billion | 63.42 Billion | 23.28 Billion | 27.52 Billion |
| Operating Income | -11.31 Billion | -11.99 Billion | -70.69 Billion | -40.72 Billion | -14.36 Billion | -12.85 Billion |
| Interest Expense | 1.49 Billion | 3.25 Billion | 3.66 Billion | 254.1 Million | 1.45 Billion | 1.39 Billion |
| Income Tax Expense | 9.68 Billion | -16.73 Billion | 1.94 Billion | -1.98 Billion | 3.85 Billion | 203.87 Million |
| Earnings before Tax | -13.78 Billion | -22.74 Billion | -36.84 Billion | -28.53 Billion | 567.7 Million | -17.36 Billion |
| Net Income | -23.47 Billion | -6.01 Billion | -118.26 Billion | -96.8 Billion | -4.85 Billion | -17.71 Billion |
| Earnings Per Share Basic | -345.65 | -69.15 | - | -1140.51 | -56.16 | -213.87 |
| Earnings Per Share Diluted | -345.65 | -69.15 | - | -1118.77 | -56.16 | -213.87 |
| Weighted Average Shares Outstanding | 67.91 Million | 86.91 Million | 83.22 Million | 84.87 Million | 86.52 Million | 82.82 Million |
| Weighted Average Shares Outstanding (Diluted) | 67.91 Million | 86.91 Million | 83.22 Million | 86.52 Million | 86.52 Million | 82.82 Million |
| Gross Margin | 0.01 | 0.06 | -0.14 | -0.20 | -0.16 | -0.02 |
| EBIT Margin | -0.46 | -0.48 | - | -1.56 | -0.16 | -0.02 |
| Profit Margin | -1.55 | -0.39 | -1.35 | -4.26 | -0.24 | -0.65 |
| EBITDA | -7.06 Billion | -7.55 Billion | - | -35.42 Billion | -3.15 Billion | -449.7 Million |
| Earnings Before Tax Margin | -0.74 | -0.77 | -0.81 | -1.79 | -0.71 | -0.47 |
HEXABS
7751
3306
1701
PIA
GNA